Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Reports outline cancer vaccines study results from Austin Hospital
May 13th, 2009
According to a study from Melbourne, Australia, "NY-ESO-1 is a highly immunogenic antigen expressed in a variety of malignancies, making it an excellent target for cancer vaccination. We recently developed a vaccine consisting of full-length recombinant NY-ESO-1 protein formulated with ISCOMATRIX adjuvant, which generated strong humoral and T-cell - mediated immune responses and seemed to reduce the risk of disease relapse in patients with fully resected melanoma." "This study examines the clinical and immunologic efficacy of the same vaccine in patients with advanced metastatic melanoma. Delayed-type hypersensitivity responses, circulating NY-ESO-1 - specific CD4(+)...
Source: Vaccine Weekly (2009-05-13)
|
